The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-27), MEI Pharma's share price is $3.05. MEI Pharma's Book Value per Share for the quarter that ended in Dec. 2023 was $8.93. Hence, MEI Pharma's PB Ratio of today is 0.34.
Good Sign:
MEI Pharma Inc stock PB Ratio (=0.34) is close to 10-year low of 0.34
The historical rank and industry rank for MEI Pharma's PB Ratio or its related term are showing as below:
MEIP'
s PB Ratio Range Over the Past 10 Years
Min: 0.34 Med: 2.41 Max: 11.36
Current: 0.34
During the past 13 years, MEI Pharma's highest PB Ratio was 11.36. The lowest was 0.34. And the median was 2.41.
MEIP's PB Ratio is ranked better than 95.34% of 1309
companies
in the Biotechnology industry
Industry Median: 2.38
vs MEIP: 0.34
During the past 12 months, MEI Pharma's average Book Value Per Share Growth Rate was 23.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -35.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -22.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -20.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of MEI Pharma was 19.90% per year. The lowest was -56.20% per year. And the median was -15.70% per year.
Back to Basics: PB Ratio
MEI Pharma PB Ratio Historical Data
The historical data trend for MEI Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MEI Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEI Pharma's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MEI Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where MEI Pharma's PB Ratio falls into.
MEI Pharma PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
MEI Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
MEI Pharma PB Ratio Related Terms
Thank you for viewing the detailed overview of MEI Pharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEIP has been successfully added to your 